Download Files:
Zardaverine
$55 – $288
Products Details
Product Description
– Zardaverine is an orally active and selective PDE3/4 inhibitor (IC50)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma[1][2][3].
Web ID
– HY-15485
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C12H10F2N2O3
References
– [1]Sun L, et al. Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition. PLoS One. 2014 Mar 5;9(3):e90627.|[2]Kips JC, et al. The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats. Clin Exp Allergy. 1993 Jun;23(6):518-23. |[3]Schudt C, et al. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl. 1991;34:379-402.
CAS Number
– 101975-10-4
Molecular Weight
– 268.22
Compound Purity
– 98.73
SMILES
– O=C1C=CC(C2=CC=C(OC(F)F)C(OC)=C2)=NN1
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 25 mg/mL (ultrasonic)
Target
– Apoptosis;Phosphodiesterase (PDE)
Isoform
– PDE3;PDE4
Pathway
– Apoptosis;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
